Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-39

@aatisket - we're a little in the dark here because the goal posts keep moving. The original 2016 announcement talked only of HF-MACE (a new measure) as the primary endpoint. Now we also have TCE which kinda makes me worried a bit because it would not be the first time that things have shifted in this trial.

But I guess at the end of the day we're looking at cells vs standard of care - so in both the treated and control groups patients will receive standard of care after an event.

So they should cancel out - but the thing that would worry me would be the potential for this change to introduce greater variation due to differences in post-event treatment and response. I guess in a year or so, we'll all know!